Fallopian Tube Cancer

Clinicians should advocate for opportunistic salpingectomy among patients undergoing surgery for benign pelvic diseases to prevent ovarian cancer, according to a consensus statement from the Ovarian Cancer Research Alliance.

When added to chemotherapy, extending the duration of bevacizumab treatment from 15 to 30 months failed to improve progression-free survival or overall survival in patients with epithelial ovarian, fallopian tube or peritoneal cancer, according to a study presented at the ASCO Annual Meeting.

The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer.

In this video, Stephen C. Rubin, MD, professor and chief of the division of gynecologic oncology and Grotzinger-Raab Chair in Surgical Oncology at Fox Chase Cancer Center in Philadelphia, spoke with Healio about a study evaluating the optimal treatment duration of bevacizumab combined with carboplatin and paclitaxel in patients with primary epithelial ovarian cancer, fallopian tube cancer or peritoneal cancer.

Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.

Maintenance therapy with olaparib extended OS compared with placebo among women with platinum-sensitive, BRCA-mutated relapsed ovarian cancer, according to the final analysis of the randomized phase 3 SOLO-2 study scheduled for presentation during the ASCO20 Virtual Scientific Program.

The FDA expanded the approval of olaparib to include its use in combination with bevacizumab for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

The FDA approved niraparib for first-line maintenance treatment of certain women with advanced epithelial ovarian, fallopian tube or primary peritoneal cancers.

The FDA expanded the approval of niraparib for gynecologic cancers.

The announcement that William G. Kaelin Jr., MD, Sir Peter J. Ratcliffe, MD, and Gregg L. Semenza, MD, PhD, were awarded the Nobel Prize in Physiology or Medicine for their discoveries of how cells sense and adapt to oxygen availability was the top story in oncology last week.